Connection
Robert Weinstein to Alendronate
This is a "connection" page, showing publications Robert Weinstein has written about Alendronate.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.851 |
|
|
|
-
Orwoll ES, Miller PD, Adachi JD, Brown J, Adler RA, Kendler D, Bucci-Rechtweg C, Readie A, Mesenbrink P, Weinstein RS. Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5?mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. J Bone Miner Res. 2010 Oct; 25(10):2239-50.
Score: 0.385
-
Weinstein RS, Roberson PK, Manolagas SC. Giant osteoclast formation and long-term oral bisphosphonate therapy. N Engl J Med. 2009 Jan 01; 360(1):53-62.
Score: 0.341
-
Weinstein RS. Glucocorticoid-induced osteonecrosis. Endocrine. 2012 Apr; 41(2):183-90.
Score: 0.105
-
Plotkin LI, Lezcano V, Thostenson J, Weinstein RS, Manolagas SC, Bellido T. Connexin 43 is required for the anti-apoptotic effect of bisphosphonates on osteocytes and osteoblasts in vivo. J Bone Miner Res. 2008 Nov; 23(11):1712-21.
Score: 0.021